Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs

Saved in:

Bibliographic Details
Main Authors:	Divya Rajagopal, Sulthan Al Rashid
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-10-01
Series:	Journal of Diabetology
Online Access:	https://journals.lww.com/jodb/fulltext/2024/15040/hepatoprotective_benefits_of_sglt_2_inhibitors_and.23.aspx
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs
by: Nikolaos Theodorakis, et al.
Published: (2025-01-01)

Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin
by: Yu-Hsiang Lin, et al.
Published: (2025-02-01)

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024-01-01)

Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?
by: Paschalis Karakasis, et al.
Published: (2024-11-01)

Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
by: Kosuke Sawami, et al.
Published: (2024-11-01)

The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
by: Sofía Echeverry-Guerrero, et al.
Published: (2024-11-01)

GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care
by: Agnieszka Parfianowicz, et al.
Published: (2025-02-01)

Long‐term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time‐varying benefit
by: Yasuo Takahashi, et al.
Published: (2024-12-01)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
by: Luis D'Marco, et al.
Published: (2021-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
by: Wenjun Sha, et al.
Published: (2020-01-01)

Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
by: Yuxin Zhang, et al.
Published: (2025-01-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
by: Qasim Zafar Iqbal, et al.
Published: (2020-01-01)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms
by: Ya-ru Chen, et al.
Published: (2024-12-01)

A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes
by: Naveenkumar Nallathambi, et al.
Published: (2024-11-01)

Antihypertensive effects of SGLT2 inhibitors; a letter to the editor on new concepts
by: Rahimeh Eskandarian, et al.
Published: (2024-06-01)

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors
by: Betül SÜMBÜL ŞEKERCİ, et al.
Published: (2025-01-01)

Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world
by: Minjung Bak, et al.
Published: (2024-12-01)

The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
by: Diana Alegre-González, et al.
Published: (2025-10-01)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
by: Vasiliki Tsampasian, et al.
Published: (2021-01-01)

Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure.
by: Minkwan Kim, et al.
Published: (2024-01-01)

Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials
by: Rahul Gupta, et al.
Published: (2024-12-01)

Comparative Effects of GLP-1 and GLP-2 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation
by: Asif Ali, et al.
Published: (2024-11-01)

Impact of SGLT2 Inhibitors on Left Ventricular Remodeling in Diabetic Patients with Acute Myocardial Infarction
by: Jun Wan MD, et al.
Published: (2024-12-01)

Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications
by: Aldona Sokołowska, et al.
Published: (2025-01-01)

Hepatoprotective Activity of Ezetimibe Against Risperidone-Induced Liver Injury in Rats
by: Atheer Majid Rashid Al-Juhaishi, et al.
Published: (2024-07-01)

Glucolipotoxicity and GLP-1 secretion
by: Dae-Hee Kim, et al.
Published: (2021-03-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)